GAMMA Investing LLC boosted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) by 106.6% during the 4th quarter, Holdings Channel reports. The fund owned 1,874 shares of the biotechnology company’s stock after buying an additional 967 shares during the period. GAMMA Investing LLC’s holdings in ADMA Biologics were worth $32,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of ADMA Biologics during the second quarter valued at about $29,000. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics during the third quarter worth $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics in the third quarter worth about $31,000. National Bank of Canada FI purchased a new position in shares of ADMA Biologics in the third quarter worth $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics during the 3rd quarter worth about $62,000. 75.68% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on ADMA. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.
Insider Transactions at ADMA Biologics
In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.70% of the company’s stock.
ADMA Biologics Stock Down 1.0 %
Shares of NASDAQ:ADMA opened at $16.32 on Wednesday. ADMA Biologics, Inc. has a fifty-two week low of $4.82 and a fifty-two week high of $23.64. The firm’s 50 day moving average price is $19.29 and its 200 day moving average price is $17.23. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of 58.29 and a beta of 0.76.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the prior year, the firm earned $0.01 EPS. As a group, equities research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
- Five stocks we like better than ADMA Biologics
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is Insider Trading? What You Can Learn from Insider Trading
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Industrial Products Stocks Investing
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report).
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.